Posts Tagged ‘tirzepatide’

What Does a New Era of Obesity Care Look Like?

June 24, 2022 — For decades now, Lee Kaplan and Caroline Apovian have led what was known as the Blackburn Course in Obesity Medicine every year at Harvard in June. This year, the name of the course has changed to Obesity Treatment 2022. It has moved to the Dartmouth Geisel School of Medicine, where Richard Rothstein has joined Kaplan […]

Tirzepatide Data Signal a New Era in Obesity Treatment

June 5, 2022 — This is what you might call a clean sweep. At the Scientific Sessions of the ADA and in NEJM yesterday, researchers unveiled detailed data on tirzepatide for obesity. When Lilly gave us a peek at these data a month ago, “Wow!” was our response. With the full details in view and peer reviewed, we tend […]

Tirzepatide Pricing Comes in Similar to Semaglutide

May 21, 2022 — Competition can be a great thing. In the past few weeks we’ve been hearing a lot about tirzepatide. The FDA just approved it for treating type 2 diabetes, hailing it as an important advance. Tirzepatide for obesity is a couple of years away, but the initial results of pivotal studies have been extremely impressive. So […]

FDA Approves “An Important Advance,” Tirzepatide

May 14, 2022 — Yesterday, FDA approved tirzepatide for type 2 diabetes, calling it “an important advance.” The brand name will be Mounjaro. This is the same drug for which its maker, Eli Lilly and Company, announced remarkable results in a phase 3 obesity study barely two weeks ago. It is the first of its kind – a dual […]

Tirzepatide Phase Three Obesity Results: Wow!

April 28, 2022 — Make no mistake. The competition to deliver better therapies for obesity is heating up in an impressive way. This morning, Eli Lilly released topline results for their first phase three trial of tirzepatide in obesity. One word sums up the reaction from top clinical scientists in obesity: “Wow!” Jeff Emmick is the vice president of […]

Racing Toward Better Anti-Obesity Medicines

February 9, 2022 — There’s a race heating up. It is a race to open the way for better obesity care and deliver better options. In this race, semaglutide (Wegovy™) has a head start. But a pack of other options are on the way. Yesterday in JAMA, results in a study of tirzepatide for treating type 2 diabetes tell […]

Suddenly Bullish on Anti-Obesity Medicines?

January 12, 2022 — It’s been a long haul. But suddenly, we’re seeing a lot of optimism about anti-obesity medicines. Skeptics are yielding to stubborn facts about the impact of obesity on health. They are also yielding to good clinical data about the benefits of sound obesity care. So, too, are they seeing that newer generations of anti-obesity medicines […]

Tirzepatide Shows Good Weight Outcomes in Diabetes

October 20, 2021 — Day by day, the prospects for treating obesity are getting better. Late on Monday, detailed results from the longest study yet of tirzepatide came out in Lancet. This was a study using this new drug in people with type 2 diabetes, but the average BMI of these patients was 33. None of them had a […]

Tirzepatide and Semaglutide Begin to Compete

June 26, 2021 — Semaglutide is getting a lot of attention right now because of its impressive effectiveness for treating obesity. But it may not have the spotlight all to itself for long. A new study in the New England Journal of Medicine tells us that tirzepatide will be giving semaglutide some serious competition. This study was for treating […]

If Wegovy Is a “Game Changer,” What Comes Next?

June 8, 2021 — The mantra for the Wegovy brand of semaglutide just approved by FDA for obesity is clear enough – game changer. Great. Obesity is not a game, but health plans treat it like a 19th century game of hot potato: “Jack’s alive, and likely to live If he dies in your hand, you’ve a forfeit to […]